DDInter336 DDInter156
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.
Celecoxib {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Azilsartan medoxomil
Celecoxib {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Olmesartan
Olmesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tasosartan
Tasosartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Celecoxib {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Celecoxib {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Celecoxib {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Potassium Iodide
Potassium Iodide {u} may lead to a major life threatening interaction when taken with {v} Azilsartan medoxomil
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Losartan
Losartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Celecoxib (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Azilsartan medoxomil (Compound)
Celecoxib (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Olmesartan (Compound) and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tasosartan (Compound) and Tasosartan (Compound) resembles Azilsartan medoxomil (Compound)
Celecoxib (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Celecoxib (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Canagliflozin (Compound) and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Celecoxib (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Potassium Iodide (Compound) and Potassium Iodide may lead to a major life threatening interaction when taken with Azilsartan medoxomil
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Losartan (Compound) and Losartan (Compound) resembles Azilsartan medoxomil (Compound)
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil